Current Report Filing (8-k)
June 16 2023 - 4:19PM
Edgar (US Regulatory)
0001477845
false
--12-31
0001477845
2023-06-16
2023-06-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
June 16, 2023
ANNOVIS BIO, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
Delaware |
001-39202 |
26-2540421 |
(State or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(I.R.S. Employer
Identification No.) |
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312
(Address of Principal Executive Offices, and
Zip Code)
(610) 727-3913
Registrant’s Telephone Number, Including
Area Code
Not
Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
Trading Symbol(s) |
Name
of each exchange on which registered |
Common Stock, par value $0.0001 per share |
ANVS |
New York Stock Exchange |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communication pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.03 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year |
On June 15, 2023, Annovis
Bio, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting,
among other things, the stockholders of the Company approved an amendment to the Annovis Bio, Inc. Amended and Restated Certificate of
Incorporation to increase the authorized number of shares of common stock from 35,000,000 to 70,000,000 shares (the “Charter Amendment’).
The Company filed the Charter Amendment with the Secretary of State of the State of Delaware following receipt of stockholder approval.
The foregoing description
is only a summary and is qualified in its entirety by reference to the complete text of the Charter Amendment, a copy of which is attached
as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 5.07 |
Submission of Matters to a Vote of Security Holders |
All
matters voted upon at the Annual Meeting were approved with the required votes. A total of 9,005,131 shares of the Company’s
common stock were entitled to vote as of April 24, 2023, the record date for the Annual Meeting, of which 6,342,582 were present in person
or by proxy at the Annual Meeting. The matters that were voted upon at the Annual Meeting, and the number of votes cast for or against,
as well as the number of abstentions and broker non-votes, as to each such matter are set forth below.
1. Election
of Directors.
The following director nominees were elected to
serve as directors of the Company, with the following votes tabulated:
|
|
For |
|
|
Withheld |
|
|
|
|
Broker Non-Vote |
Michael Hoffman |
|
|
3,994,452 |
|
|
40,827 |
|
|
|
|
|
2,307,303 |
Maria Maccecchini |
|
|
3,998,045 |
|
|
37,234 |
|
|
|
|
|
2,307,303 |
Claudine Bruck |
|
|
3,941,691 |
|
|
93,588 |
|
|
|
|
|
2,307,303 |
Reid McCarthy |
|
|
3,993,879 |
|
|
41,400 |
|
|
|
|
|
2,307,303 |
Mark White |
|
|
3,987,711 |
|
|
47,568 |
|
|
|
|
|
2,307,303 |
2.
Amendment of the 2020 Equity Incentive Plan.
The amendment to the Company’s
Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 35,000,000 to 70,000,000
was approved, with the following votes tabulated:
For |
|
|
Against |
|
|
Abstain |
5,699,648 |
|
|
633,577 |
|
|
9,357 |
Item 9.01 |
Financial Statement and Exhibits |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ANNOVIS BIO, INC. |
|
|
|
Date: June 16, 2023 |
By: |
/s/ Henry Hagopian |
|
|
Name: |
Henry Hagopian |
|
|
Title: |
Chief Financial Officer |
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Aug 2023 to Aug 2024